GEOGRAPHIC ATROPHY
Clinical trials for GEOGRAPHIC ATROPHY explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy tested to halt blinding eye disease
Disease control OngoingThis early-stage study is testing a one-time gene therapy injection called OCU410 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes progressive vision loss. The trial aims to see if the treatment is safe and if it can slow th…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Eye drug safety under the microscope in major Real-World study
Disease control OngoingThis study is monitoring the safety and real-world use of Syfovre (pegcetacoplan) injections in patients with geographic atrophy, a condition that causes progressive vision loss from age-related macular degeneration. It will follow 300 patients who are already prescribed this tre…
Matched conditions: GEOGRAPHIC ATROPHY
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New eye injection trial aims to halt blinding disease
Disease control OngoingThis study is testing the safety and early effectiveness of an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Up to 30 participants will receive injections of t…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE1, PHASE2 • Sponsor: Michelle Abou-Jaoude • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New pill aims to halt blinding eye disease in major trial
Disease control OngoingThis study is testing whether a daily oral medication called Tinlarebant can slow the progression of geographic atrophy (GA), an advanced form of age-related macular degeneration that causes permanent vision loss. About 429 participants with GA will be randomly assigned to take e…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New eye drug aims to halt blinding disease
Disease control OngoingThis study is testing a medicine called BI 1584862 to see if it can slow the progression of geographic atrophy, a severe form of dry age-related macular degeneration that causes permanent vision loss. About 150 adults aged 50+ with this condition will be randomly assigned to rece…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New eye injection aims to halt blinding disease in seniors
Disease control OngoingThis study is testing if a new drug called ANX007, given as a monthly injection into the eye, can slow down vision loss in people with geographic atrophy, a late-stage form of age-related macular degeneration. About 660 participants will be randomly assigned to receive either the…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE3 • Sponsor: Annexon, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New eye shot aims to slow blinding eye disease
Disease control OngoingThis study is testing a new investigational eye injection called BI 771716 against an already approved treatment, pegcetacoplan, for people with geographic atrophy. Geographic atrophy is an advanced form of age-related macular degeneration that causes progressive, permanent visio…
Matched conditions: GEOGRAPHIC ATROPHY
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC